During Michaelmas Term, OxTalks will be moving to a new platform (full details are available on the Staff Gateway).
For now, continue using the current page and event submission process (freeze period dates to be advised).
If you have any questions, please contact halo@digital.ox.ac.uk
In 2000, John Krystal’s group at Yale discovered that a single sub-anaesthetic dose of intravenous ketamine provided several days of symptomatic relief in a small group of depressed patients. This effect has been widely confirmed and has led recently to the licensing of intranasal esketamine for the treatment of patients with refractory depressive illness. In this talk we will describe the development of ketamine as an antidepressant, discuss the possible mechanisms involved in its action, and appraise the likely utility of ketamine and esketamine for clinical use in the NHS.